Saif Abdulkarim Alenizi, M.B.,Ch.B.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Survival | 5 | 2024 | 3890 | 0.530 |
Why?
|
| Heart Transplantation | 2 | 2020 | 3310 | 0.520 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2024 | 84 | 0.500 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 975 | 0.460 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2020 | 1365 | 0.430 |
Why?
|
| Graft Rejection | 3 | 2024 | 4499 | 0.360 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2019 | 31 | 0.320 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 3111 | 0.260 |
Why?
|
| Hypernatremia | 1 | 2016 | 78 | 0.250 |
Why?
|
| Amphotericin B | 1 | 2013 | 140 | 0.210 |
Why?
|
| Diuretics | 1 | 2016 | 613 | 0.200 |
Why?
|
| Transplantation, Homologous | 2 | 2020 | 4860 | 0.190 |
Why?
|
| Immune Tolerance | 2 | 2020 | 2324 | 0.180 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2021 | 62 | 0.180 |
Why?
|
| Antithrombins | 1 | 2013 | 295 | 0.180 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2011 | 134 | 0.170 |
Why?
|
| Histamine H2 Antagonists | 1 | 2011 | 168 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 2011 | 245 | 0.160 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 4270 | 0.150 |
Why?
|
| Antifungal Agents | 1 | 2013 | 769 | 0.150 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 1995 | 0.150 |
Why?
|
| Isoantigens | 1 | 2020 | 562 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2013 | 962 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2013 | 1166 | 0.140 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2020 | 333 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 1158 | 0.130 |
Why?
|
| Recurrence | 3 | 2024 | 8501 | 0.130 |
Why?
|
| Heparin | 1 | 2013 | 1630 | 0.130 |
Why?
|
| Isoantibodies | 1 | 2020 | 681 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 553 | 0.130 |
Why?
|
| Myeloid Cells | 1 | 2020 | 839 | 0.120 |
Why?
|
| Point Mutation | 1 | 2020 | 1590 | 0.120 |
Why?
|
| Antibodies | 1 | 2021 | 2417 | 0.110 |
Why?
|
| Kidney | 2 | 2021 | 7066 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2011 | 2499 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 2 | 2024 | 2495 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 6220 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2013 | 3461 | 0.090 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 2570 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2020 | 2395 | 0.090 |
Why?
|
| Thrombosis | 1 | 2013 | 2949 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2013 | 4862 | 0.070 |
Why?
|
| Critical Illness | 1 | 2020 | 2744 | 0.070 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3800 | 0.070 |
Why?
|
| Myocardium | 1 | 2020 | 4760 | 0.070 |
Why?
|
| Brazil | 2 | 2021 | 1248 | 0.070 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 125 | 0.060 |
Why?
|
| Smad Proteins | 1 | 2016 | 157 | 0.060 |
Why?
|
| Water-Electrolyte Balance | 1 | 2016 | 325 | 0.060 |
Why?
|
| Europe | 2 | 2021 | 3423 | 0.050 |
Why?
|
| Mice | 2 | 2020 | 81819 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10261 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2016 | 23601 | 0.050 |
Why?
|
| Animals | 4 | 2020 | 168764 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 5753 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 22332 | 0.050 |
Why?
|
| Qatar | 1 | 2011 | 40 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2024 | 683 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 18293 | 0.040 |
Why?
|
| Mycoses | 1 | 2013 | 389 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2020 | 205 | 0.040 |
Why?
|
| Male | 8 | 2024 | 363698 | 0.040 |
Why?
|
| Fibrosis | 1 | 2016 | 2070 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 598 | 0.040 |
Why?
|
| Autophagy | 1 | 2016 | 1351 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 4528 | 0.030 |
Why?
|
| Humans | 11 | 2024 | 765968 | 0.030 |
Why?
|
| Drug Approval | 1 | 2013 | 818 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2024 | 2233 | 0.030 |
Why?
|
| Program Development | 1 | 2011 | 1295 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 1672 | 0.030 |
Why?
|
| Middle Aged | 6 | 2024 | 223009 | 0.030 |
Why?
|
| Risk Factors | 4 | 2024 | 74840 | 0.030 |
Why?
|
| Incidence | 2 | 2024 | 21480 | 0.030 |
Why?
|
| United States | 4 | 2021 | 72903 | 0.030 |
Why?
|
| Adult | 5 | 2024 | 223044 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 9514 | 0.020 |
Why?
|
| Survival Rate | 1 | 2024 | 12795 | 0.020 |
Why?
|
| Biopsy | 1 | 2021 | 6763 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2024 | 81514 | 0.020 |
Why?
|
| Female | 6 | 2024 | 396112 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 8041 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4209 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2020 | 5343 | 0.020 |
Why?
|
| Age Factors | 1 | 2020 | 18380 | 0.010 |
Why?
|
| Prognosis | 1 | 2024 | 29922 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 39193 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2024 | 15747 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8703 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2020 | 24282 | 0.010 |
Why?
|
| Time Factors | 1 | 2020 | 40065 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2011 | 54802 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 59489 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 65188 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 88835 | 0.010 |
Why?
|
| Aged | 1 | 2020 | 171117 | 0.000 |
Why?
|